Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study
Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study
复制标题
DOI：
10.1186/cc12737
复制
发表时间：
2013-01-01
期刊：
影响因子：
15.1
通讯作者：
Moss, Marc
中科院分区：
文献类型：
--
作者：
Clark, Brendan J.;Bull, Todd M.;Moss, Marc
简介：我们试图确定是否较高水平的新生物标志物生长分化因子-15（GDF-15）与急性呼吸窘迫综合征（ARDS）患者的不良结局和肺血管功能障碍（PVD）的存在相关。方法：我们对急性呼吸窘迫综合征网络液体和导管治疗（FACT）试验中招募的患者进行了回顾性队列研究。入组FACT试验的患者接受了肺动脉导管（PAC），在同一研究日有可用的血浆，并有足够的血流动力学数据来确定是否存在PVD。Logistic回归被用来确定GDF-15水平和60天mortals.Results之间的关联：在513例参加FACT试验分配到接受PAC的患者中，400例被纳入本分析。与GDF-15水平在第一四分位数的患者（12%）相比，GDF-15水平在第三四分位数的患者（28%）或第四四分位数的患者（49%）在60天的死亡率显著较高（P
Introduction: We sought to determine whether higher levels of the novel biomarker growth differentiation factor-15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS).Methods: We conducted a retrospective cohort study in patients enrolled in the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment (FACT) Trial. Patients enrolled in the FACT Trial who received a pulmonary artery catheter (PAC), had plasma available from the same study day and sufficient hemodynamic data to determine the presence of PVD were included. Logistic regression was used to determine the association between GDF-15 level and 60-day mortality.Results: Of the 513 patients enrolled in the FACT Trial assigned to receive a PAC, 400 were included in this analysis. Mortality at 60 days was significantly higher in patients whose GDF-15 levels were in the third (28%) or fourth (49%) quartile when compared to patients with GDF-15 levels in the first quartile (12%) (P